It was revealed that DKI metrics with whole-tumor volume histogram analysis, especially the K75th parameter, yielded more preferable AUC and specificity values for predicting KRAS/NRAS/BRAF mutations than ADC and D values, and thus may potentially serve as an optimal imaging biomarker for the prediction of KRAS/NRAS/BRAF mutations for guiding targeted therapy.
This abstract and the presentation materials are available to members only; a login is required.